Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study

SIMPLE SUMMARY: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer, with a high recurrence rate. Since treatment of BRCA(mut) TNBC patients with PARP inhibitor (PARPi), targeting the nuclear protein PARP1, shows varied responses, its therapeutic efficacy is currently eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Sankaranarayanan, Ramya Ambur, Peil, Jennifer, Vogg, Andreas T. J., Bolm, Carsten, Terhorst, Steven, Classen, Arno, Bauwens, Matthias, Maurer, Jochen, Mottaghy, Felix, Morgenroth, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750932/
https://www.ncbi.nlm.nih.gov/pubmed/35008392
http://dx.doi.org/10.3390/cancers14010230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750932/
https://www.ncbi.nlm.nih.gov/pubmed/35008392
http://dx.doi.org/10.3390/cancers14010230

Ejemplares similares